Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam Open-Label Extension in Alzheimer's Disease
NCT05575076Phase 3Terminated
- Sponsor
- Cassava Sciences
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Started Nov 2022; status: terminated.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05575076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05575076.